Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Journal of Pharmacoepidemiology and Risk Management 2020; 12(2): 79-84
Published online September 30, 2020
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Gayoon Park,MD1, Jae Eun Sohn,MD1, Mira Moon,MS1, Ju Yeun Lee, PhD2, Hye-Ryun Kang, MD, PhD1,3,4 and Dong Yoon Kang, MD, PhD1,3
박가윤1, 손재은1, 문미라1, 이주연2, 강혜련1,3,4, 강동윤1,3
Correspondence to:Dong Yoon Kang, MD, PhD
Drug Safety Monitoring Center, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-2844, Fax: +82-2-2072-3644
E-mail: kdy@snu.ac.kr
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: Eperisone is the most widely prescribed muscle relaxant in Korea. However, few studies have investigated the adverse drug reactions (ADRs) of eperisone in the Korean population. A study is needed to analyze the ADR characteristics of eperisone in Koreans, especially the risk of anaphylaxis compared to other spasmolytic agents. Methods: The individual safety case report (ISCR) of 1989 to 2015 from the Korea Institute of Drug Safety and Risk Management (KIDS) have been analyzed. Frequent ADRs of eperisone were listed by using World Health Organization Adverse Reaction Terminology classification. The proportional reporting ratio (PRR) has been calculated to estimate the risk of anaphylaxis caused by eperisone compared to other central muscle relaxants. Results: 9,036 cases (1.1%) were related to central muscle relaxants among a total of 860,224 ISCRs from 1989 to 2015. Eperisone was the first place as 3,030 cases (33.5%). The symptoms of eperisone-induced ADRs were mostly similar with those of other central muscle relaxants. However, the anaphylaxis, which is a serious ADR that could be life-threatening, was significantly more reported in ADRs related to eperisone than those related to other central muscle relaxants (PRR = 4.80, 95% confidence interval: 2.73-8.41, p ＜ 0.001). Conclusion: Eperisone is highly related to drug-induced anaphylaxis compared to other central muscle relaxants. (JPERM 2020;12:79-84): Central muscle relaxants; Drug-related side effects and adverse reactions; Drug hypersensitivity; Anaphylaxis
Keywords Central muscle relaxants, Drug-related side effects and adverse reactions, Drug hypersensitivity, Anaphylaxis
